TLR4 and bacterial infectious disease: recently demonstrated the ciVAX platform using mesoporous silica particles coupled with the TLR4 agonist lipid A and a Fc‐mannose‐binding lectin to bind bacterial components to protect mice from bacterial infections.[34] This platform demonstrated the ability to promote antibody production, decrease bacterial burden, and prevent mortality, but whether the protective effects could be produced by the biomaterial itself, or the numerous factors added to the biomaterial is unknown.